Showing results (111-120 of 3,348) with videos related to

Sort By:
Pageof 335
Pharmacoeconomics|March 2, 2018
The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence ReviewAlex Diamantopoulos, Emily Wright, Katerina Vlahopoulou, et al.
Pharmacoeconomics|December 17, 2013
Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorialVakaramoko Diaby, Georges Adunlin, Alberto J Montero
Pharmacoeconomics|December 17, 2013
Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic modelsEleanor M Heather, Katherine Payne, Mark Harrison, et al.
Pharmacoeconomics|November 23, 2013
The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidanceGerardus W J Frederix, Johan G C van Hasselt, Jan H M Schellens, et al.
Pharmacoeconomics|November 6, 2013
Pharmaceutical pricing: an empirical study of market competition in Chinese hospitalsJing Wu, Judy Xu, Gordon Liu, et al.
Pharmacoeconomics|January 17, 2022
Projected New-Onset Cardiovascular Disease by Socioeconomic Group in AustraliaKaitlyn Hastings, Clara Marquina, Jedidiah Morton, et al.
Pharmacoeconomics|December 15, 2021
Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their CaregiversC Simone Sutherland, Pollyanna Hudson, Stephen Mitchell, et al.
Pharmacoeconomics|November 11, 2021
Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy ManagementNoman Paracha, Pollyanna Hudson, Stephen Mitchell, et al.
Pharmacoeconomics|February 18, 2021
Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration DimensionJing Wu, Shitong Xie, Xiaoning He, et al.
Pharmacoeconomics|February 9, 2017
Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPaul Tappenden, Christopher Carroll, John W Stevens, et al.
Pageof 335